News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

InVasc Therapeutics Initiates Phase IIa Proof of Concept Study with INV-144 in Patients with Chronic Kidney Disease


6/24/2011 9:32:51 AM

ATLANTA--(BUSINESS WIRE)--InVasc Therapeutics, Inc., announced today that it has initiated a Phase IIa, proof of concept (POC), clinical trial with INV-144, a combination drug of losartan with alpha Lipoic Acid (ALA), to slow the progression of chronic kidney disease (CKD) in hypertensive diabetic patients. The trial, which is being conducted under an IND in the United States, is a multi-center, randomized, double-blind, active-controlled study that will compare the treatment of patients with losartan alone versus losartan plus ALA. Each arm of the trial will enroll 40 patients. Losartan is already approved for the treatment of patients with CKD. ALA, a powerful antioxidant, is a widely used nutraceutical in the U.S.; and in Europe, it has been approved for treating diabetic peripheral neuropathy.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES